

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**In re application of:** Hodge et al.

**Application No.** 10/590,844

**Filed:** August 24, 2006

**Confirmation No.** 8385

**For:** SCREENING AGENTS THAT DECREASE  
PATHOGENICITY BY DECREASING  
RAB11A ACTIVITY

**FILED VIA EFS**

**Examiner:** Sheridan Swope

**Art Unit:** 1652

**Attorney Reference No.** 6395-68026-07

FILED VIA EFS  
COMMISSIONER FOR PATENTS

**INFORMATION DISCLOSURE STATEMENT**  
**PURSUANT TO 37 C.F.R. § 1.97(b)**

Listed on the accompanying form PTO-1449 and submitted herewith is one English-language document. Applicants respectfully request that this document be listed as a reference cited on the issued patent.

Applicants filed this Information Disclosure Statement (IDS) before the mailing of a first Office action after the filing of request for continued examination under § 1.114. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicants to file this IDS, please charge any such fees, or credit overpayment, to Deposit Account No. 02-4550.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 595-5300  
Facsimile: (503) 595-5301

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By /Karri Kuenzli Bradley/

Karri Kuenzli Bradley, Ph.D.  
Registration No. 56,300

cc: Docketing